Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.  In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

3Oct

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver MeetingĀ®

24Sep

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

14Aug

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

Q2 2018 Quarterly Results